Thermo Fisher Scientific Inc. $TMO Stake Trimmed by Coho Partners Ltd.

Coho Partners Ltd. cut its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 43.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 69,551 shares of the medical research company’s stock after selling 53,070 shares during the quarter. Thermo Fisher Scientific accounts for 4.3% of Coho Partners Ltd.’s portfolio, making the stock its 6th largest position. Coho Partners Ltd.’s holdings in Thermo Fisher Scientific were worth $33,733,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in TMO. LongView Wealth Management acquired a new position in Thermo Fisher Scientific in the 3rd quarter worth approximately $231,000. Exchange Traded Concepts LLC lifted its holdings in shares of Thermo Fisher Scientific by 109.6% in the third quarter. Exchange Traded Concepts LLC now owns 5,934 shares of the medical research company’s stock valued at $2,878,000 after purchasing an additional 3,103 shares in the last quarter. Matrix Asset Advisors Inc. NY grew its holdings in shares of Thermo Fisher Scientific by 0.6% during the third quarter. Matrix Asset Advisors Inc. NY now owns 21,511 shares of the medical research company’s stock valued at $10,433,000 after buying an additional 134 shares in the last quarter. Cohen Investment Advisors LLC raised its position in Thermo Fisher Scientific by 5.3% during the third quarter. Cohen Investment Advisors LLC now owns 7,005 shares of the medical research company’s stock valued at $3,398,000 after buying an additional 355 shares during the period. Finally, Perennial Advisors LLC lifted its stake in Thermo Fisher Scientific by 0.8% in the 3rd quarter. Perennial Advisors LLC now owns 16,111 shares of the medical research company’s stock worth $7,814,000 after acquiring an additional 132 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Trading Up 1.4%

Thermo Fisher Scientific stock opened at $575.85 on Tuesday. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $610.97. The company’s fifty day moving average price is $570.03 and its two-hundred day moving average price is $499.31. The company has a market capitalization of $216.35 billion, a price-to-earnings ratio of 33.27, a PEG ratio of 4.21 and a beta of 0.90. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The business had revenue of $11.12 billion for the quarter, compared to analyst estimates of $10.90 billion. During the same quarter in the prior year, the firm posted $5.28 EPS. The firm’s revenue for the quarter was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific declared that its Board of Directors has approved a share buyback plan on Thursday, November 6th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical research company to reacquire up to 2.4% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its shares are undervalued.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 9.94%.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Michel Lagarde sold 32,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $583.39, for a total value of $18,668,480.00. Following the sale, the chief operating officer owned 65,480 shares of the company’s stock, valued at $38,200,377.20. This trade represents a 32.83% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Marc N. Casper sold 17,104 shares of the company’s stock in a transaction that occurred on Friday, October 24th. The stock was sold at an average price of $573.54, for a total value of $9,809,828.16. Following the transaction, the chief executive officer owned 113,762 shares of the company’s stock, valued at approximately $65,247,057.48. This trade represents a 13.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 149,271 shares of company stock worth $86,507,282 in the last ninety days. 0.33% of the stock is owned by insiders.

Analyst Ratings Changes

A number of brokerages have recently weighed in on TMO. Barclays upped their target price on Thermo Fisher Scientific from $585.00 to $625.00 and gave the company an “overweight” rating in a report on Thursday, October 23rd. JPMorgan Chase & Co. boosted their price objective on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a research report on Thursday, October 9th. Weiss Ratings reissued a “hold (c)” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, October 14th. The Goldman Sachs Group started coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, December 9th. They issued a “buy” rating and a $685.00 price target on the stock. Finally, Leerink Partners lifted their price objective on Thermo Fisher Scientific from $545.00 to $580.00 and gave the company an “outperform” rating in a research report on Wednesday, October 22nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $616.60.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.